Toft Group Places John W. Beck as Chief Financial Officer for Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) in Los Angeles, CA

Executive search firm Toft Group has placed John W. Beck as Chief Financial Officer at Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) in Los Angeles, CA. Ritter Pharmaceuticals is a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance.

Mr. Beck joins Ritter Pharmaceuticals with over 25 years of experience in leadership roles across finance, accounting and compliance, capital markets, fundraising, mergers and acquisitions and commercial operations in life sciences and high technologies companies. Mr. Beck was previously CEO of both Wellspring Water Technologies of West Tech Medical, companies he co-founded. Prior to that, Mr. Beck was CFO for Ardea Biosciences. Before joining Ardea, Mr. Beck spent 10 years with Metabasis Therapeutics as a co-founder and CFO. Mr. Beck has also served as finance director at Neurocrine Biosciences. Mr. Beck currently serves on the boards of advisors for August Therapeutics and Pinnacle Medical Holdings.

Robin Toft, President and CEO of Toft Group, said, “Mr. Beck’s significant experience in public company management, his relationships within the investor community and his background in licensing and mergers and acquisitions will serve an important function for Ritter Pharmaceuticals as it moves into phase 3 clinical development with RP-G28 and prepares to commercialize this important asset, either alone or with partners, and build value for investors.”

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. The company’s lead product candidate, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions of people worldwide. RP-G28 has been studied in Phase 2 trials, and is expected to commence Phase 3 clinical development in the second quarter of 2018. Ritter Pharmaceuticals, Inc. is further exploring the therapeutic potential that gut microbiome changes may have on treating/preventing a variety of diseases including gastrointestinal diseases, cancer, metabolic, and liver disease.